Longitudinal follow-up of breast cancer patients with the tumor markers CA 549 and CA 15.3

1995 ◽  
Vol 10 (1) ◽  
pp. 30-34 ◽  
Author(s):  
L. Vankrieken ◽  
F. Heureux ◽  
J. Longueville ◽  
R. De Hertogh
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Clinical Situation ◽  
Breast Cancer Patients ◽  
Significant Information ◽  
Ca 15.3 ◽  
Cutoff Levels

In order to verify the efficiency of the tumor markers CA 15.3 and CA 549 in the follow-up of breast cancer patients, it was necessary first to check the cutoff levels of each tumor marker in women with an increased age-related risk, but with no evidence of disease. From 132 serum samples in this age group, we confirmed the CA 549 cutoff level of 12.1 U/ml. However, the cutoff of CA 15.3 was 34 U/ml, which is higher than previously reported in the literature. Fifty-two breast cancer patients with or without metastases at the time of entry into the study were followed for 2 to 3 years with both tumor markers. The sensitivity, specificity and the test efficiency for the presence of metastases were analyzed with each tumor marker. Taking into account the different cutoff levels, we concluded that both tumor markers can be used independently to follow the clinical situation of patients. In several cases an increase in both tumor markers was observed before a clinical diagnosis of metastases could be made. Combination of these two tumor markers gave no more significant information about the patient's clinical situation than each tumor marker alone.

Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma

1995 ◽  
Vol 10 (1) ◽  
pp. 24-29 ◽  
Author(s):  
L. Rodríguez De Paterna ◽  
F. Arnaiz ◽  
J. Estenoz ◽  
B. Ortuño ◽  
E. Lanzós
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Serum Levels ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Combined Use ◽  
Malignant Breast

Serum levels of CEA, CA 15.3 and CA 27.29 were measured during the follow-up of 499 breast cancer patients. Studies included three different groups of women: 82 blood donors free of disease, 42 patients with non-malignant breast diseases and 499 breast cancer patients. After the determinaion of cut-off values, serum levels of tumor markers did not show significant elevations in benign breast diseases. On the basis of our results CA 15.3 (sensitivity = 57%; accuracy = 87%) was the most effective marker, CA 27.29 (sensitivity = 62%; accuracy = 83%) was the most sensitive and CEA (sensitivity = 45%; accuracy = 81%) was the least sensitive and effective marker. The combined use of markers was evaluated by step-wise logistic regression analysis. The regression coefficients showed that CA 15.3 (coeff. = 2.97) and CA 27.29 (coeff. = 1.46) were suitable for the detection of possible metastases during follow-up. Finally, we studied the relationship between pT, pN, pM and circulating levels of CA 15.3 and CA 27.29.

Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27.29

1992 ◽  
Vol 7 (1) ◽  
pp. 43-46 ◽  
Author(s):  
M. Correale ◽  
I. Abbate ◽  
G. Gargano ◽  
A. Catino ◽  
C.D. Dragone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Breast Disease ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Lower Specificity ◽  
Apparently Healthy

Evaluation of a radioimmunoassay for a new tumor marker, named CA 27.29, recently proposed for use in breast cancer patients, is reported in this study. After considering the analytical performance, the clinical study was directed to a control group of 66 apparently healthy subjects (Controls), a group of 25 women with benign breast disease (BBD) and a group of 164 breast cancer patients divided into primary before any treatment (M-), in follow-up with no evidence of disease (NED) and presence of metastases (M+). When compared to CA 15.3, our results showed similar sensitivity of both markers with a slightly lower specificity for CA 27.29. In some cases, however, CA 27.29 elevation appears earlier than CA 15.3 as a sign of metastases. We thus propose their associated use.

Ca 15.3 as a Tumour Marker in Breast Cancer

1987 ◽  
Vol 2 (3) ◽  
pp. 135-142 ◽  
Author(s):  
Peter Schmidt-Rhode ◽  
Klaus-Dieter Schulz ◽  
Gerhard Sturm ◽  
Anette Raab-Frick ◽  
Helge Prinz
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Tumour Marker ◽  
Primary Treatment ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Healthy Females

CA 15.3 is an antigenic determinant associated with human mammary carcinomas. Two murine monoclonal antibodies have been raised against the determinants, and an immunoradiometric assay (IRMA-Kit, Centocor, USA) has been developed to determine the antigen levels in plasma of cancer patients. Based on the 99% confidence limit of healthy women, plasma values above 30 U/ml are considered abnormal. Plasma samples from 357 women were examined in the present study. Healthy females (n = 84) ranged below the cut-off level between < 10 and 29 U/ml. Higher values were found in 12.5% of benign breast diseases and in 23.6% of breast cancer patients, including all stages. Depending on the stage of the disease, there were elevated levels in 11% of operable breast cancer patients preoperatively, in 7% of the cases with no evidence of disease after primary treatment and in 63.5% ofpatients with disseminated mammary carcinoma. In metastasized breast cancer the frequency and the degree of abnormal titers were closely related to the extent of the metastatic disease. Follow-up examinations of 63 patients under cytotoxic therapy showed CA 15.3 changes correlating well with the clinical course in up to 90% of the antigen positive cases. The present data indicate that CA 15.3 may be useful in the surveillance of breast cancer patients. However in our study one third of the patients with metastatic breast cancer did not show any increase in CA 15.3 and must be regarded as antigen negative.

scholarly journals BREAST CANCER

2007 ◽  
Vol 14 (01) ◽  
pp. 98-104
Author(s):  
MUKHTAR AHMAD ◽  
MUHAMMAD TAHIR MAJEED ◽  
MOHAMMAD JAWAID SABZWARI ◽  
Muhammad Riaz ◽  
Muhammad Umair
Keyword(s):  
Breast Cancer ◽  
Sialic Acid ◽  
Breast Carcinoma ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Sensitivity And Specificity ◽  
Colorimetric Method ◽  
Enzyme Linked Immunosorbent Assay ◽  
Breast Cancer Patients

Cancer is a group of diseases with uncontrolled cellular proliferation. Breast cancer accounts for 25% of all cancer deaths in females worldwide. Monoclonal antibodies are used for the detection of tumor markers in order for rapid diagnosis and understanding of the nature of cancer at molecular level. On co-fetal antigens like carcinoembryonic antigen 15-3 (CA 15-3) are a new generation of clinically useful tumor markers. Elevated levels of CA 15-3 are related to stages in primary breast cancer, tumor size and nodal status. Significantly elevated sialic acid concentrations havebeen found in breast cancer patients and show correlation with tumor stage. Although total sialic acid has been used as general cancer marker but its role as diagnostic and prognostic marker has not been reported. Objective: This project was designed to study the sensitivity and specificity of sialic acid in breast cancer patients and was compared to CA 15-3, which is one of the most specific markers of breast cancer. Study design: Comparative study. Setting: Shaikh Zayed Medical Complex. Material and Methods: 66 breast cancer patients and 30 normal individuals (controls) were included in the study to compare serum sialic acid with CA 15-3 as tumor marker. Sialic acid was estimated by colorimetric method while CA 15-3 by Enzyme-Linked Immunosorbent Assay. Results: The sensitivity and specificity of CA 15-3 in breast cancer patients was 62.5% and 80% while that of sialic acid was 62% and 76% respectively. The sensitivity of CA 15-3 and sialic acid in patients with ductal breast carcinoma was 62.5% and 54.16% whereas the specificity of CA 15-3 and sialic acid was 80% and 76% respectively. The sensitivity of CA 15-3 and sialic acid in patients with lobular breast carcinoma was 83.33% and 75% whereas the specificity of CA 15-3 and sialic acid was 80% and 76% respectively. Conclusion: It was concluded that sialic acid can be used as a tumor marker in breast cancer patients and has sensitivity and specificity similar to CA15-3. However, CA 15-3appears to have better predictive value. 

Sign in / Sign up

Export Citation Format

Share Document